2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
[HTML][HTML] Empagliflozin in heart failure with a preserved ejection fraction
Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …
Gliflozins in the management of cardiovascular disease
E Braunwald - New England Journal of Medicine, 2022 - Mass Medical Soc
Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure with preserved ejection fraction, but additional data …
heart failure in patients with heart failure with preserved ejection fraction, but additional data …
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
E Brown, HJL Heerspink, DJ Cuthbertson, JPH Wilding - The Lancet, 2021 - thelancet.com
SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …
[HTML][HTML] Cardiovascular and renal outcomes with empagliflozin in heart failure
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure in patients regardless of the presence or absence of …
hospitalization for heart failure in patients regardless of the presence or absence of …
Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …